HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors
- Resource Type
- Article
- Source
- In
Lung Cancer August 2022 170:1-10 - Subject
- Language
- ISSN
- 0169-5002